Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
Phase 3
Terminated
- Conditions
- COVID-19
- Interventions
- Other: PlaceboBiological: Asunercept
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT05639192
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇫🇷CHU de Limoges - Hopital Dupuytren, Limoges, France
🇫🇷Georges Pompidou European Hospital, Paris, France
APG101 in Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Drug: Treatment with APG101Procedure: Bone marrow collectionProcedure: Blood drawings
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT01736436
- Locations
- 🇩🇪
Universitaetsklinik Heidelberg, Medizinische Klinik V, Haematologie, Onkologie & Rheumatologie, Heidelberg, Germany
🇩🇪Universitaetsmedizin Mannheim, III. Medizinische Klinik, Haematologie und Onkologie, Mannheim, Germany
APG101 in Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- Procedure: Blood drawingDrug: APG101
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 84
- Registration Number
- NCT01071837
- Locations
- 🇩🇪
Universitätsklinik Heidelberg, Abteilung Neuroonkologie, Heidelberg, Germany
🇩🇪Universitätsklinikum Tuebingen, Strahlenonkologie, Tuebingen, Germany
🇩🇪Charite Universitätsmedizin Berlin, Klinik für Neurochirugie, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath